CSPC Pharmaceutical Group Limited (HKG:1093)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
8.33
-0.37 (-4.25%)
Oct 22, 2026, 3:40 PM HKT

CSPC Pharmaceutical Group Stock Forecast

Stock Price Forecast

According to 24 analysts polled by S&P Global, CSPC Pharmaceutical Group stock has a consensus rating of "Buy" and an average price target of $12.67. The average 1-year stock price forecast is 52.10% higher than the current stock price, while the lowest is $8.00 (-3.96%) and the highest is $19.36 (+132.41%).

Price Target: $12.67 (+52.10%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$8.00$12.67$12.00$19.36
Change-3.96%+52.10%+44.06%+132.41%
* Price targets were last updated on Sep 9, 2026.

Analyst Ratings

The average analyst rating for CSPC Pharmaceutical Group stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingMay '26Jun '26Jul '26Aug '26Sep '26Oct '26
Strong Buy151414171717
Buy233344
Hold322111
Sell111111
Strong Sell333111
Total242323232424

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
DBS
DBS
Buy
Initiates
$13.70
BuyInitiates$13.70+64.47%Sep 9, 2026
Unknown Analyst
UBS
No rating
UBS
Buy
Maintains
$10.90 → $11.80
BuyMaintains$10.90 → $11.80+41.66%Aug 27, 2026
Unknown Analyst
Citic Securities
No rating
Citic Securities
Buy
Maintains
$18.00
BuyMaintains$18.00+116.09%Aug 25, 2026
Jefferies
Jefferies
Sell
Maintains
$8.00
SellMaintains$8.00-3.96%Aug 24, 2026
Unknown Analyst
Huatai Securities
No rating
Huatai Securities
Buy
Maintains
$19.36
BuyMaintains$19.36+132.41%Aug 22, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
33.88B
from 26.01B
Increased by 30.29%
Revenue Next Year
31.43B
from 33.88B
Decreased by -7.25%
EPS This Year
0.79
from 0.31
Increased by 154.79%
EPS Next Year
0.59
from 0.79
Decreased by -25.34%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
27.87B30.94B31.45B29.01B26.01B33.88B
Revenue Growth
11.73%11.02%1.66%-7.76%-10.35%30.29%
Gross Profit
21.14B22.26B22.18B20.30B17.06B25.00B
Gross Margin
75.84%71.94%70.51%69.97%65.59%73.79%
Operating Income
6.25B6.76B7.02B5.37B3.96B10.73B
Net Income
5.61B6.09B5.87B4.33B3.88B8.93B
EPS
----0.310.79
EPS Growth
-----17.93%154.79%
Forward PE
15.7013.8612.059.7617.089.02
Dividend / Share
0.150.190.260.240.260.40
Dividend Growth
41.58%25.66%35.08%-7.75%9.50%55.41%
Free Cash Flow
----3.91B6.73B
No. Analysts
-----21
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue202620272028
High37.8B
Avg33.9B
Low31.7B

Revenue Growth

Revenue Growth202620272028
High
45.5%
Avg
30.3%
Low
21.9%

EPS Forecast

EPS202620272028
High0.94
Avg0.79
Low0.65

EPS Growth

EPS Growth202620272028
High
206.1%
Avg
154.8%
Low
109.6%